このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Penumbra 将来の成長

Future 基準チェック /46

Penumbra利益と収益がそれぞれ年間26.2%と13.4%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に10.6% 24.8%なると予測されています。

主要情報

26.2%

収益成長率

24.8%

EPS成長率

Medical Equipment 収益成長	16.7%
収益成長率	13.4%
将来の株主資本利益率	10.6%
アナリストカバレッジ	Good
最終更新日	12 Jun 2024

今後の成長に関する最新情報

Recent updates

Penumbra: Future Upside Drivers In Fundamental, Sentimental And Valuation Factors

Jun 22

Getting In Cheap On Penumbra, Inc. (NYSE:PEN) Might Be Difficult

Jun 02

We're Not Worried About Penumbra's (NYSE:PEN) Cash Burn

Apr 01

Penumbra Non-GAAP EPS of $0.16 beats by $0.01, revenue of $221.22M beats by $4.19M

Feb 23

Penumbra Riding Higher On Upcoming Launches And Rerating

Jan 12

Penumbra: Today's Best Medical Equipment Nearby Cap-Gain Buy

Nov 03

Penumbra cut to Neutral at Citi on macro concerns

Oct 05

Penumbra, Asahi team up to bring blood clot removing device Indigo to Japan

Sep 22

Penumbra stock rises ~11% after announcing European launch of catheters for stroke care

Sep 07

Sector Rerating Has Cast A Shadow Over Penumbra

Aug 18

Penumbra gains as RBC initiates at Outperform with 59% upside

Jul 18

Penumbra: Multiple Downside Targets, Rescued By Long-Term Value Proposition

Jun 10

Penumbra A Little Beaten Down Despite Strong Growth Opportunities

Mar 01

業績と収益の成長予測

NYSE:PEN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,666	205	183	N/A	10
12/31/2025	1,443	150	159	118	14
12/31/2024	1,241	107	116	85	14
3/31/2024	1,096	93	104	122	N/A
12/31/2023	1,059	91	81	97	N/A
9/30/2023	995	41	47	62	N/A
6/30/2023	938	29	1	19	N/A
3/31/2023	885	6	-56	-38	N/A
12/31/2022	847	-2	-75	-56	N/A
9/30/2022	830	-31	-90	-66	N/A
6/30/2022	806	-19	-40	-17	N/A
3/31/2022	782	-6	-3	19	N/A
12/31/2021	748	5	-12	10	N/A
9/30/2021	710	34	0	17	N/A
6/30/2021	671	16	-39	-23	N/A
3/31/2021	592	-5	-60	-42	N/A
12/31/2020	560	-16	-58	-33	N/A
9/30/2020	539	-10	-55	-26	N/A
6/30/2020	527	11	-34	-1	N/A
3/31/2020	556	39	-7	23	N/A
12/31/2019	547	48	5	27	N/A
9/30/2019	523	45	32	29	N/A
6/30/2019	495	15	7	18	N/A
3/31/2019	471	12	7	16	N/A
12/31/2018	445	7	19	29	N/A
9/30/2018	420	9	-12	20	N/A
6/30/2018	392	28	6	21	N/A
3/31/2018	363	13	7	21	N/A
12/31/2017	334	5	N/A	13	N/A
9/30/2017	311	-7	N/A	3	N/A
6/30/2017	294	5	N/A	-2	N/A
3/31/2017	279	9	N/A	-9	N/A
12/31/2016	263	15	N/A	-13	N/A
9/30/2016	245	18	N/A	-11	N/A
6/30/2016	228	6	N/A	-21	N/A
3/31/2016	205	3	N/A	-20	N/A
12/31/2015	186	1	N/A	-21	N/A
9/30/2015	167	0	N/A	-18	N/A
6/30/2015	149	-1	N/A	-17	N/A
3/31/2015	138	-1	N/A	-9	N/A
12/31/2014	126	-1	N/A	-6	N/A
12/31/2013	89	1	N/A	-3	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PENの予測収益成長率 (年間26.2% ) は貯蓄率 ( 2.4% ) を上回っています。

収益対市場: PENの収益 ( 26.2% ) はUS市場 ( 14.8% ) よりも速いペースで成長すると予測されています。

高成長収益: PENの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: PENの収益 ( 13.4% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: PENの収益 ( 13.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PENの自己資本利益率は、3年後には低くなると予測されています ( 10.6 %)。

Penumbra 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Penumbra, Inc. Reiterates Earnings Guidance for the Year 2024

Penumbra, Inc. Provides Earnings Guidance for the Full Year 2024

Penumbra, Inc. Provides Earnings Guidance for the Full Year 2023

Price target decreased by 8.5% to US$301

Consensus EPS estimates increase by 16%

Penumbra, Inc. Updates Revenue Guidance for the Full Year 2023

Recent updates

Returns At Penumbra (NYSE:PEN) Appear To Be Weighed Down

Penumbra: Appeal Improves As Operating Leverage Continues

Co-Founder notifies of intention to sell stock

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Penumbra, Inc. Reiterates Earnings Guidance for the Year 2024

Penumbra, Inc., Annual General Meeting, Jun 05, 2024

Penumbra, Inc. Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots

Penumbra, Inc.'s (NYSE:PEN) Earnings Haven't Escaped The Attention Of Investors

Penumbra, Inc. to Report Q1, 2024 Results on May 07, 2024

Estimating The Intrinsic Value Of Penumbra, Inc. (NYSE:PEN)

Executive VP notifies of intention to sell stock

Full year 2023 earnings: EPS exceeds analyst expectations

Penumbra, Inc. Provides Earnings Guidance for the Full Year 2024

Now 21% overvalued after recent price rise

Now 23% overvalued after recent price rise

Penumbra, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Some Investors May Be Worried About Penumbra's (NYSE:PEN) Returns On Capital

Executive VP notifies of intention to sell stock

Penumbra, Inc. Announces First Patient in STORM-PE RCT Enrolled Evaluating Penumbra's Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash for Treatment of Acute Pulmonary Embolism

A Look At The Fair Value Of Penumbra, Inc. (NYSE:PEN)

Now 21% undervalued after recent price drop

Penumbra, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Penumbra, Inc. Announces Latest STRIKE-PE Data Evaluating Penumbra's Indigo Aspiration System with Lightning

Price target decreased by 8.5% to US$301

Penumbra: Appeal Improves, Just Not Appealing Yet

Co-Founder exercised options and sold US$2.0m worth of stock

Now 20% undervalued after recent price drop

Penumbra, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Returns On Capital Signal Tricky Times Ahead For Penumbra (NYSE:PEN)

Co-Founder exercised options and sold US$2.8m worth of stock

Executive VP notifies of intention to sell stock

Penumbra: Consolidation Does Nothing To Change Long-Term Thesis, Reiterate Buy

A Look At The Intrinsic Value Of Penumbra, Inc. (NYSE:PEN)

Co-Founder notifies of intention to sell stock

Consensus EPS estimates increase by 16%

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Co-Founder exercised options and sold US$3.0m worth of stock

Penumbra, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Penumbra (NYSE:PEN) Has Some Way To Go To Become A Multi-Bagger

Penumbra: Future Upside Drivers In Fundamental, Sentimental And Valuation Factors

Co-Founder exercised options and sold US$3.1m worth of stock

Executive VP notifies of intention to sell stock

Penumbra Expands Computer-Aided Thrombectomy Offerings with Lightning Bolt 7 Technology Designed to Rapidly Remove Blood Clots with Modulated Aspiration

Getting In Cheap On Penumbra, Inc. (NYSE:PEN) Might Be Difficult

Penumbra, Inc. Updates Revenue Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Executive VP exercised options and sold US$154k worth of stock

We're Not Worried About Penumbra's (NYSE:PEN) Cash Burn

Independent Director notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Price target increased by 11% to US$291

Price target increased by 7.2% to US$272

Penumbra Non-GAAP EPS of $0.16 beats by $0.01, revenue of $221.22M beats by $4.19M

Presiding Independent Director notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock

Penumbra, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Penumbra Riding Higher On Upcoming Launches And Rerating

Penumbra, Inc. Launches Latest Innovation in Mechanical Thrombectomy, Lightning Flash

Price target increased to US$228

Executive VP notifies of intention to sell stock

Executive VP exercised options and sold US$259k worth of stock

Penumbra, Inc. Launches First Hands-Free, Full Body Virtual Reality-Based Offering for Rehabilitation, Expanding Real System Platform

Insufficient new directors

Third quarter 2022 earnings released: US$0.06 loss per share (vs US$0.24 profit in 3Q 2021)

Penumbra, Inc. Provides Revenue Guidance for the Year 2023

Penumbra: Today's Best Medical Equipment Nearby Cap-Gain Buy

Executive VP exercised options and sold US$256k worth of stock